glucagon + glucagon-like peptide-1

**Glucagon + glucagon-like peptide-1** is a dual hormone combination therapy designed to leverage complementary effects for metabolic control, primarily in obesity and type 2 diabetes. Glucagon, a peptide hormone from pancreatic alpha cells, elevates blood glucose by promoting hepatic glycogenolysis and gluconeogenesis while enhancing energy expenditure and inducing lipolysis to counteract GLP-1-induced weight loss plateaus. Glucagon-like peptide-1 (GLP-1), an incretin hormone from intestinal L-cells, activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite via central nervous system signaling. This co-agonist approach aims to improve glycemic control and achieve greater weight reduction than GLP-1 monotherapy, with investigational formulations typically administered via subcutaneous injection. No approved products exist under this exact name, but dual agonists like oxyntomodulin analogs or experimental fusions target these receptors.